4.7 Article

Label-free single-substrate quantitative protein assay based on optical characteristics of cholesteric liquid crystals

Journal

JOURNAL OF MOLECULAR LIQUIDS
Volume 331, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.molliq.2021.115756

Keywords

Optical biosensor; Cholesteric liquid crystal; Transmission spectrometry; Protein assay; Bovine serum albumin; Label-free biosensor

Funding

  1. Ministry of Science and Technology, Taiwan [107-2112-M-009-012-MY3, 109-2320-B-309-001]

Ask authors/readers for more resources

By adjusting the thickness and helical pitch ratio of the CLC film, both qualitative and quantitative biosensing capabilities were demonstrated with E7/R811 and E7/R5011 CLC films, showing potential for protein detection and quantification.
Cholesteric liquid crystal (CLC) is characterized by the selective reflection in the Bragg condition for constructive interference. Instead of assembling a LC cell with a pair of glass substrates, only a single glass substrate modified with vertical alignment reagent and layered with a CLC film of 3.4 +/- 0.2 mu min thickness was utilized in this study for the detection of bovine serum albumin (BSA). By fine-tuning the ratio of the thickness d to the helical pitch P of the CLC film, both qualitative and quantitative biosensing capabilities were demonstrated with an E7/R811 CLC (d/P close to but smaller than unity) and an E7/R5011 CLC (d/P>> 1) film, respectively. The E7/R811 film was in the unwound homeotropic state in the absence of BSA, but transitioned to the fingerprint state at 10(-9) to 10(-6)-g/ml BSA and to the planar state between 10(-5) and 10(-2)-g/ml BSA. Quantitative protein assay based on E7/R5011 CLCs was established through transmission spectrometric analysis, and detection sensitivity was optimized by adjusting the Bragg reflection wavelength. A limit of detection of 5.9 x 10(-9) g/ml was achieved for the CLC film consisting of 2.0-wt% R5011 in the nematic host E7 and exhibiting a Bragg reflection wavelength of 700 nm. As amajority of clinical assays are performed on a single solid substrate, the CLC-based, single-substrate biosensing platform allows for better integration with current technologies. Besides, the protein array employed in this work can be further miniaturized and converted to a protein microarray format to facilitate highthroughput analysis. (C) 2021 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available